News Switch to Faricimab May Extend Dosing Intervals in nAMD by Medscape • 2026/10/09 • 0 Comments Switching from aflibercept to faricimab is linked to longer dosing intervals and better fluid control over 3 years among patients with treatment-resistant neovascular age-related macular degeneration. Medscape Medical News